Clinical Trials Browser

Phase 2 × niraparib × 1 year × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04288687 2026-03-04

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Phase 2 Completed

11 enrolled 13 charts

Prostate Adenocarcinoma

NCT04947254 2026-02-19

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT06433219 2026-02-18

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Phase 2 Active not recruiting

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT05442749 2026-02-17

PARPi-PANC

Phase 2 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT05601440 2026-02-11

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT04068753 2026-02-10

STAR

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT05718323 2026-02-06

RAISE

Phase 2 Recruiting

SCLC,Extensive Stage

NCT05700721 2026-02-05

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Phase 2 Recruiting

Brain Neoplasms

NCT03601923 2026-01-28

Niraparib in Patients With Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04992013 2026-01-23

Niraparib in Tumors Metastatic to the CNS

Phase 2 Active not recruiting

Neoplasm Metastasis, Central Nervous System Neoplasms

NCT04221503 2026-01-08

Niraparib/TTFields in GBM

Phase 2 Active not recruiting

Glioblastoma

NCT05689021 2026-01-07

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03983993 2026-01-05

NIPAVect

Phase 2 Active not recruiting

26 enrolled 8 charts

Gastrointestinal

Colorectal Neoplasms

NCT03431350 2025-12-23

QUEST

Phase 2 Active not recruiting

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT04592237 2025-12-23

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02854436 2025-12-22

Galahad

Phase 2 Completed

289 enrolled 18 charts

Prostatic Neoplasms

NCT04701307 2025-12-15

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Phase 2 Active not recruiting

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05526989 2025-12-04

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Phase 2 Recruiting

Penile Neoplasms

NCT04779151 2025-12-01

NIRADO

Phase 2 Terminated

GastrointestinalGenitourinaryHead & Neck

Biliary Tract Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms

NCT06180356 2025-11-28

ANALLISA

Phase 2 Recruiting

Ovarian Neoplasms

NCT06964165 2025-11-26

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Phase 2 Terminated

36 enrolled 11 charts

Ovarian Neoplasms

NCT05169437 2025-10-29

PAVO

Phase 2 Terminated

22 enrolled 17 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT05515575 2025-10-20

A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

Phase 2 Active not recruiting

Sarcoma

NCT06392841 2025-10-20

HARMONY

Phase 2 Withdrawn

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT04641247 2025-09-29

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Phase 2 Recruiting

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT06527690 2025-09-29

REPRESENTATION

Phase 2 Withdrawn

Prostatic Neoplasms

NCT06747845 2025-09-16

ParpVax2

Phase 2 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

NCT04030559 2025-08-26

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04080284 2025-08-19

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Phase 2 Completed

Uterine Neoplasms, Endometrial Neoplasms

NCT04409002 2025-08-15

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Phase 2 Completed

18 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04493060 2025-08-07

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Phase 2 Completed

22 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03326193 2025-07-31

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 2 Completed

105 enrolled 29 charts

Ovarian Neoplasms

NCT04584255 2025-07-28

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT03574779 2025-07-15

OPAL

Phase 2 Completed

77 enrolled 8 charts

Ovarian Neoplasms

NCT05335993 2025-07-10

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Phase 2 Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03783949 2025-06-11

EUDARIO

Phase 2 Completed

122 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05297864 2025-05-23

OU-SCC-PI-4G

Phase 2 Terminated

15 enrolled 13 charts

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

NCT05455424 2025-05-15

NERO

Phase 2 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma, Recurrence

NCT06212583 2025-05-01

KNIGHTS

Phase 2 Recruiting

Prostatic Neoplasms

NCT05990192 2025-04-22

SOPRANO

Phase 2 Recruiting

Ovarian Neoplasms

NCT05523440 2025-03-28

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Phase 2 Terminated

Ovarian Neoplasms, Endometrial Neoplasms